Not Yet Recruiting
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
NCT06845241
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
- Locations
-
- Fujian Cancer Hospital Fuzhou, Fujian, China
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
- Henan Cancer Hosptital Zhengzhou, Henan, China
- The First Affiliated Hospital of Nanchang University Nanchang, Jiangxi, China